U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C5H4N4O3
Molecular Weight 168.1103
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of URIC ACID

SMILES

O=C1NC2=C(N1)C(=O)NC(=O)N2

InChI

InChIKey=LEHOTFFKMJEONL-UHFFFAOYSA-N
InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12)

HIDE SMILES / InChI

Description

Uric acid, generated from the metabolism of purines, has proven and emerging roles in human disease. Humans produce large quantities of uric acid. Excess serum accumulation of uric acid can lead to a type of arthritis known as gout. Hyperuricemia may increase risk factors for cardiovascular disease. High serum uric acid was associated with higher risk of type 2 diabetes and other diseases.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown
Diagnostic
Unknown
Diagnostic
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Mice: twice daily with 10 mg per dose for 7 days
Route of Administration: Intraperitoneal
In Vitro Use Guide
Uric acid (5 mg/dL) significantly increased MCP-1 production by rat vascular smooth muscle cells at 3, 6, and 24 hours when compared with that of control media.